RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1
Advanced Biology · 2025
DOI: 10.1002/adbi.202500220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Biology, 2025. Verfasst von Gang He und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Fengxian District Central Hospital, Shanghai, 385686, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, E2F1 Transcription Factor, Esophageal Neoplasms, CDC2 Protein Kinase. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, State key laboratory open project, Suzhou new Diagnosis and Treatment Technology Research.
Abstract (Originalsprache)
Esophageal cancer is a major disease that seriously threatens human health. Ribosomal RNA biogenesis is implicated in tumorigenesis, while the small nucleolar RNAs (snoRNAs) are responsible for post‐transcriptional modifications of ribosomal RNAs during biogenesis, which are identified as potential markers of various cancers. The clinical significance, biological behavior, and potential molecular mechanism of the nucleolar small nuclear ribonucleoprotein RRP9 in esophageal squamous cell carcinoma (ESCC), which is a major pathological type of esophageal cancer, are investigated in this study. It is found that RRP9 is abnormally highly expressed in ESCC tissues and is closely associated with poor prognosis. Furthermore, it is found that RRP9 could regulate the cell cycle protein‐dependent kinase CDK1 to promote ESCC progression in vitro and in vivo. Mechanistically, RRP9 promotes ESCC progression through enhancing the E2F1‐mediated transcriptional regulation of CDK1. Collectively, the results defined RRP9 as an important tumor driver in ESCC that acted by activating oncogenic signaling by the E2F1‐CDK1 pathway, and suggested RRP9 as a candidate therapeutic target for ESCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Fengxian District Central Hospital, Shanghai, 385686, China.
- Department of Thoracic Surgery, Institute of Thoracic Surgery, The First Affiliated Hospital of Soochow University, No.899 Pinghai Road, Suzhou, Jiangsu, 215005, China.
- Oncology department, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 74565, China.
- Thoracic and Cardiothoracic Surgery Department, Suzhou Ninth People's Hospital, Suzhou, Jiangsu, 604074, China.
- Medical College of Soochow University, Suzhou, Jiangsu, 74565, China.
- Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, 215005, China.
ORCID-Profile: Jiashi Xiong, Dong Jiang
Förderung
- National Natural Science Foundation of China
- State key laboratory open project
- Suzhou new Diagnosis and Treatment Technology Research
- Suzhou Health Talent Training Project
- Boxi Culture Project of First Affiliated Hospital of Soochow University
- Shanghai Fengxian District (social) science and technology development project
Zitieren
APA
He, G., Wan, Y., Zhu, Y., Peng, B., Shao, S., Zou, X., Han, Z., Li, J., Ju, S., Tong, X., Zhao, J., Liang, H., Zhang, L., Xiong, J., & Jiang, D. (2025). RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1. Advanced Biology. https://doi.org/10.1002/adbi.202500220
Vancouver
He G, Wan Y, Zhu Y, Peng B, Shao S, Zou X, et al. RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1. Advanced Biology. 2025. doi:10.1002/adbi.202500220
BibTeX
@article{He2025,
author = {He, Gang and Wan, Yilong and Zhu, Yanbo and Peng, Bo and Shao, Shengxiang and Zou, Xinyi and Han, Zhenyu and Li, Jiaxi and Ju, Sheng and Tong, Xin and Zhao, Jun and Liang, Hansi and Zhang, Liuqing and Xiong, Jiashi and Jiang, Dong},
title = {RRP9 Promotes Esophageal Squamous Cell Carcinoma Progression through E2F1 Transcriptional Regulation of CDK1},
journal = {Advanced Biology},
year = {2025},
doi = {10.1002/adbi.202500220}
}
EUVIMED